Incorporating new biomarkers such as NGAL, KIM-1, and LFABP may enable timely diagnostic and preventive measures, especially for high-risk patients [33], reducing the progression to severe AKI and improving overall patient outcomes. The gene discussed is LCN2; the disease is acute kidney injury.